(MENAFN) New York-based biopharmaceutical firm Bristol-Myers Squibb Co (BMS) agreed to acquire biotechnology company Amylin Pharmaceuticals Inc for about USD5.3 billion in cash, Reuters reported.
The deal, according to Bristol-Myers, will help extend its portfolio of diabetes treatments with the addition of drugs Byetta and Bydureon which Amylin makes.
Bristol-Myers also said it reached a partnership deal with UK-based AstraZeneca Plc to jointly develop Amylin's products after the takeover deal is sealed. AstraZeneca will pay USD3.4 billion in cash for these rights.
a further collaboration upon an existing partnership between the two pharmaceutical makers in diabetes treatments.
Amylin has been looking for potential buyers in April after rejecting a previous USD3.5 billion takeover bid from Bristol-Myers, and facing pressure from activist investor Carl Icahn.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.